Septerna (NASDAQ:SEPN) Earns Buy Rating from Analysts at Truist Financial

Truist Financial started coverage on shares of Septerna (NASDAQ:SEPN) in a report released on Monday, Marketbeat Ratings reports. The brokerage issued a buy rating and a $34.00 price objective on the stock.

Other research analysts have also recently issued reports about the company. HC Wainwright increased their price target on Septerna from $26.00 to $30.00 and gave the company a “buy” rating in a research report on Tuesday, November 11th. Wells Fargo & Company raised Septerna from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $18.00 to $28.00 in a research report on Friday, November 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Septerna in a research note on Wednesday, October 8th. Cantor Fitzgerald reissued an “overweight” rating and issued a $25.00 target price on shares of Septerna in a research note on Friday, September 5th. Finally, Wall Street Zen upgraded shares of Septerna from a “sell” rating to a “buy” rating in a report on Sunday, November 16th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $29.25.

Septerna Trading Up 1.2%

Septerna stock opened at $26.55 on Monday. Septerna has a 1-year low of $4.17 and a 1-year high of $29.74. The company has a fifty day simple moving average of $23.54 and a 200 day simple moving average of $16.66. The company has a market cap of $1.19 billion, a P/E ratio of -17.58 and a beta of 3.80.

Septerna (NASDAQ:SEPN) last issued its quarterly earnings results on Monday, November 10th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of $0.19 by ($0.28). The business had revenue of $21.50 million for the quarter, compared to the consensus estimate of $24.50 million. Septerna had a negative return on equity of 17.98% and a negative net margin of 266.77%. On average, equities research analysts forecast that Septerna will post -7.11 EPS for the current year.

Insider Activity at Septerna

In related news, SVP Daniel D. Long sold 3,501 shares of the business’s stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $18.06, for a total transaction of $63,228.06. Following the transaction, the senior vice president directly owned 92,911 shares of the company’s stock, valued at approximately $1,677,972.66. The trade was a 3.63% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On Septerna

Several institutional investors and hedge funds have recently modified their holdings of the stock. Russell Investments Group Ltd. bought a new position in shares of Septerna in the third quarter valued at about $36,000. Covestor Ltd grew its stake in Septerna by 55.8% in the 3rd quarter. Covestor Ltd now owns 3,620 shares of the company’s stock valued at $68,000 after buying an additional 1,296 shares during the last quarter. BNP Paribas Financial Markets raised its holdings in Septerna by 88.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 4,155 shares of the company’s stock valued at $78,000 after acquiring an additional 1,945 shares during the period. Deutsche Bank AG lifted its position in Septerna by 53.3% during the first quarter. Deutsche Bank AG now owns 15,968 shares of the company’s stock worth $92,000 after acquiring an additional 5,549 shares during the last quarter. Finally, Stoneridge Investment Partners LLC acquired a new stake in Septerna during the first quarter worth approximately $107,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.